FRIENDSWOOD, Texas--(BUSINESS WIRE)--
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share three abstracts supporting the ability of its TissueCypher® test to predict risk of progression to esophageal cancer in patients with Barrett’s esophagus (BE) at the Digestive Disease Week (DDW) 2024 Annual Meeting, being held May 18-21, 2024, in Washington, D.C.
“We are committed to advancing care for patients with BE in an effort to reduce the incidence of esophageal cancer and importantly, to help save patients’ lives by informing earlier, potentially life-saving interventions,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences. “The data we are sharing at DDW 2024 in collaboration with renowned GI experts from the U.S. and abroad further expand the substantial clinical evidence supporting our TissueCypher test and its ability to improve the care that BE patients receive.”
The following abstracts will be presented at DDW 2024 (all times Eastern Time). Abstracts will be available on the and to conference attendees in the DDW meeting planner and mobile app after 12:01 a.m. on Sunday, May 19, 2024.
-
Podium presentation title: The Tissue Systems Pathology Test Enables Risk-Aligned Management for Patients with Barrett’s Esophagus
Presenter and Lead Author: Lucas Duits, M.D., Ph.D., Amsterdam University Medical Centers
Abstract #: 392
Session Type: Research Forum
Session #: 3265
Session Title: Advances in Barrett's Esophagus
Date & Time: Sunday, May 19, 11:15-11:30 a.m. -
Title: The Tissue Systems Pathology Test Predicts Risk of Malignant Progression in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis
Presenter and Lead Author: Ashley Tran, M.D., Keck School of Medicine, University of Southern California (USC)
Abstract #: Su1266
Session Type: Poster Session
Session #: 7110
Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
Session Date & Time: Sunday, May 19, 12:30-1:30 p.m. -
Title: The Tissue Systems Pathology Test Provides Clinically Actionable Risk-Stratification in Patients with Barrett’s Esophagus: A Multicenter U.S. Clinical Experience
Presenter and Lead Author: Harshit Khara, M.D. FACG, FASGE, Geisinger Health System
Abstract #: Su1267
Session Type: Poster Session
Session #: 7110
Session Title: Barrett's Esophagus and Esophagogastric Junction Neoplasia - Epidemiology, Risk factors, Screening, Surveillance, Treatment and Outcomes
Session Date & Time: Sunday, May 19, 12:30-1:30 p.m.
Visit Castle at DDW 2024
For more information on the above abstracts and the TissueCypher test, visit Castle at booth 3737; a complete list of Castle’s activities at DDW 2024 can be found at . Key events include the following:
Product Theater
-
BEyond the diagnosis: personalized, precision medicine in the management of Barrett’s esophagus
Panel discussion to include: Emmanuel Gorospe, M.D., MPH, FACP, FACG, FASGE, GI medical director at Castle Biosciences; Dan Lister, M.D., FACS, FAFS, surgeon and director of the Arkansas Heartburn Treatment Center, and co-founder and president elect of the American Foregut Society; Dr. Farhan Quader, M.D., interventional gastroenterologist at NorthShore University Hospital in Chicago; Sarah Enslin, PA-C, Division of Gastroenterology and Hepatology at the University of Rochester Medical Center Rochester in New York
Location: DDW Product Theater 1
Date & Time: Tuesday, May 21, 12-12:45 p.m.
ASGE Theater Talks
-
A modern approach to the clinical management of patients with Barrett’s esophagus
Presenter: Harshit Khara, M.D., FACG, FASGE, Geisinger Medical Center
Date & Time: Saturday, May 18, 10:15-10:45 a.m.
-
Leveraging clinically impactful risk stratification for patients with Barrett’s esophagus
Presenter: John C. Lipham, M.D., Keck Medicine of USC
Date & Time: Monday, May 20, 2:45-3:15 p.m.
Additionally, Castle is collaborating with several organizations, including the ASGE, Esophageal Cancer Action Network, American Muslim Gastroenterologist Network, American Foregut Society and Women in Endoscopy on various educational and networking events taking place throughout the meeting.
About Digestive Disease Week® (DDW)
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 18-21, 2024. The meeting showcases more than 4,400 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at .
About TissueCypher® Barrett’s Esophagus Test
The TissueCypher Barrett’s Esophagus test is Castle’s precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett’s esophagus (BE). The TissueCypher Barrett’s Esophagus test is indicated for use in patients with endoscopic biopsy confirmed BE that is graded non-dysplastic (NDBE), indefinite for dysplasia (IND) or low-grade dysplasia (LGD); its clinical performance has been supported by 13 peer-reviewed publications of BE progressor patients with leading clinical centers around the world. The test received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS) in March 2022.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit and connect with us on , , and .
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: (i) Castle’s ability to advance care for patients with BE; and (ii) the ability of the TissueCypher test to predict the risk of progression to esophageal cancer in patients with BE and to help save patients’ lives by informing earlier, potentially life-saving interventions. The words “can,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results shown in this study, including with respect to the discussion of TissueCypher in this press release; actual application of our TissueCypher test may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
View source version on businesswire.com:
